UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): October 8, 2015

 

Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

0-27436	94-3171940
(Commission File Number)	(IRS Employer Identification No.)

  

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080

---

(Address of principal executive offices and zip code)

(650) 244-4990 

(Registrant’s telephone number including area code)

 

---

(Registrant’s former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  

Item 8.01.  Other Events.

 

On October 8, 2015, Titan Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it had received approval to list its common stock on the NASDAQ Capital Market effective at the opening of trading on Monday, October 12, 2015. The Company’s stock will trade under the symbol TTNP.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01.  Financial Statement and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.		Description
99.1		Press Release dated October 8, 2015

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

 

TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle                          
       Name: Sunil Bhonsle
      Title: President

Dated: October 9, 2015